MX369117B - Antagonistas del receptor ep4 para el tratamiento de cancer. - Google Patents

Antagonistas del receptor ep4 para el tratamiento de cancer.

Info

Publication number
MX369117B
MX369117B MX2016008394A MX2016008394A MX369117B MX 369117 B MX369117 B MX 369117B MX 2016008394 A MX2016008394 A MX 2016008394A MX 2016008394 A MX2016008394 A MX 2016008394A MX 369117 B MX369117 B MX 369117B
Authority
MX
Mexico
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
treatment
Prior art date
Application number
MX2016008394A
Other languages
English (en)
Inventor
Take Yukinori
Koizumi Shinichi
Okumura Takako
Nonomura Kazuhiko
Original Assignee
Askat Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askat Inc filed Critical Askat Inc
Publication of MX369117B publication Critical patent/MX369117B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Esta invención provee un medicamento para el tratamiento de cáncer, el cual causa una reducción del cáncer. Esta invención se relaciona con el uso de un compuesto el cual tiene actividades inhibidoras en contra el receptor de prostaglandina E2 (receptor EP4) y es representado por la siguiente formula general (I), (II), (III), o (IV), o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal para la fabricación de un medicamento para el tratamiento de cáncer. La invención se relaciona con un método para el tratamiento de cáncer que comprende administrar el compuesto o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal a humanos o animales. El compuesto o una sal farmacéuticamente aceptable de éste, o la composición farmacéutica pueden ser usadas en combinación con uno o más agentes activos secundarios. (ver Fórmulas).
MX2016008394A 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer. MX369117B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009104568 2009-04-22
JP2010015445 2010-01-27
PCT/JP2010/057114 WO2010123049A1 (ja) 2009-04-22 2010-04-22 癌治療のための選択的ｅｐ４受容体拮抗物質

Publications (1)

Publication Number Publication Date
MX369117B true MX369117B (es) 2019-10-28

Family

ID=43011165

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011011058A MX345032B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer.
MX2016008394A MX369117B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011011058A MX345032B (es) 2009-04-22 2010-04-22 Antagonistas del receptor ep4 para el tratamiento de cáncer.

Country Status (12)

Country Link
US (5) US8921391B2 (es)
EP (3) EP2422779B1 (es)
JP (1) JP5668219B2 (es)
KR (1) KR101575706B1 (es)
CN (2) CN102421429B (es)
BR (1) BRPI1014174B8 (es)
CA (1) CA2754702C (es)
ES (3) ES2960438T3 (es)
HK (2) HK1214763A1 (es)
MX (2) MX345032B (es)
RU (1) RU2563817C2 (es)
WO (1) WO2010123049A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422779B1 (en) 2009-04-22 2016-01-06 RaQualia Pharma Inc. Selective ep4 receptor antagonistic substance for treatment of cancer
CN106572993B (zh) * 2014-05-23 2019-07-16 卫材R&D管理有限公司 Ep4拮抗剂在制备治疗癌症的药物中的应用
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CA3096546A1 (en) * 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2020014445A1 (en) * 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Ep4 inhibitors and synthesis thereof
CA3113468A1 (en) * 2018-09-27 2020-04-02 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
DK3860998T3 (da) 2018-10-05 2024-03-25 Annapurna Bio Inc Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet
EP3983412A4 (en) * 2019-06-11 2023-12-27 Teon Therapeutics, Inc. PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND THEIR USES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054808A1 (fr) * 1999-03-16 2000-09-21 Toray Industries, Inc. Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
AU6836200A (en) 1999-08-10 2001-03-05 Glaxo Group Limited Use of ep4 receptor ligands in the treatment of, inter alia, neuropathic pain and colon cancer
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
WO2001062708A1 (fr) * 2000-02-22 2001-08-30 Ono Pharmaceutical Co., Ltd. Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
EP1494667A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
AU2003223119A1 (en) 2002-04-16 2003-10-27 Astellas Pharma Inc. Medicament for preventing and/or treating chronic rejection
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
CN1946391A (zh) * 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
KR20070006891A (ko) 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
EA200601830A1 (ru) * 2004-05-04 2007-04-27 Пфайзер Инк. Ортозамещённые арильные или гетероарильные амидные соединения
CA2600510C (en) 2005-03-11 2010-11-02 Pfizer Inc. Crystal forms of an imidazole derivative
EP1885722B1 (en) * 2005-05-19 2011-11-16 Merck Canada Inc. Quinoline derivatives as ep4 antagonists
EP2422779B1 (en) 2009-04-22 2016-01-06 RaQualia Pharma Inc. Selective ep4 receptor antagonistic substance for treatment of cancer
KR101539436B1 (ko) 2013-12-30 2015-07-24 주식회사 효성 가스 절연 개폐기의 부분 방전 검출 장치

Also Published As

Publication number Publication date
US20150111920A1 (en) 2015-04-23
KR20120096402A (ko) 2012-08-30
CN102421429B (zh) 2016-08-17
JP5668219B2 (ja) 2015-02-12
MX2011011058A (es) 2011-11-18
HK1214763A1 (zh) 2016-08-05
CN105596320A (zh) 2016-05-25
US9688674B2 (en) 2017-06-27
EP3431085C0 (en) 2023-10-11
BRPI1014174B8 (pt) 2021-05-25
US10611761B2 (en) 2020-04-07
US8921391B2 (en) 2014-12-30
CA2754702C (en) 2016-06-07
CA2754702A1 (en) 2010-10-28
HK1166700A1 (zh) 2012-11-09
US20200188367A1 (en) 2020-06-18
RU2563817C2 (ru) 2015-09-20
US20120088723A1 (en) 2012-04-12
US10947235B2 (en) 2021-03-16
EP2965756B1 (en) 2018-10-10
CN102421429A (zh) 2012-04-18
EP2965756A1 (en) 2016-01-13
EP2422779A4 (en) 2013-06-19
BRPI1014174A2 (pt) 2016-04-05
EP2422779A1 (en) 2012-02-29
BRPI1014174B1 (pt) 2020-10-06
ES2960438T3 (es) 2024-03-04
EP2422779B1 (en) 2016-01-06
ES2562814T3 (es) 2016-03-08
CN105596320B (zh) 2019-03-22
EP3431085A1 (en) 2019-01-23
EP3431085B1 (en) 2023-10-11
KR101575706B1 (ko) 2015-12-10
ES2698508T3 (es) 2019-02-05
US11840530B2 (en) 2023-12-12
WO2010123049A1 (ja) 2010-10-28
JPWO2010123049A1 (ja) 2012-10-25
MX345032B (es) 2017-01-12
US20220073510A1 (en) 2022-03-10
US20170253595A1 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
MX345032B (es) Antagonistas del receptor ep4 para el tratamiento de cáncer.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PH12015501678A1 (en) Inhibitors of influenza viruses replication
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ602510A (en) Treatment of lupus nephritis using laquinimod
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
MX338554B (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
NZ563774A (en) Inhibitors of VEGF receptor and HGF receptor signaling
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
NZ595767A (en) Composition for the treatment of prostate cancer
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
TNSN07419A1 (en) Methods for treating drug resistant cancer
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TNSN08506A1 (en) Substituted carboxamides
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia